INTRODUCTION - For All Patients from Any Country

Thank you for taking part in this online survey of patients & survivors. This survey will be used as part of Lymphoma Canada's, Cutaneous Lymphoma Foundation and the Canadian Skin Patient Alliance group submission to the pan-Canadian Oncology Drug Review (www.pCODR.ca). The pan-Canadian Oncology Drug Review (pCODR) assesses cancer drugs for clinical and cost-effectiveness compared to other treatments that are currently available, and makes recommendations to provinces and territories to guide their drug funding decisions.

The purpose of this survey is to help develop a complete and thorough submission to help governments understand the value of new cancer drugs to patients and caregivers. The drug that will soon be reviewed by pCODR for Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL) is Ledaga (also referred to as Valchlor).

Your feedback is extremely important and may help improve access to this new drug for patients. The greater the response the better our data will be. The survey results may also be shared with other international groups who are submitting patient experience data for drug submissions. We will ensure no identifying information is shared.
 
YOU DO NOT HAVE TO BE A CANADIAN RESIDENT TO RESPOND TO THIS SURVEY; WE APPRECIATE INPUT FROM ALL PATIENTS WITH MF-CTCL.
 
If you have any questions, concerns, or technical difficulties while completing this survey please contact Kaitlyn Beyfuss-Laski at: kaitlyn@lymphoma.ca

Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other information that could lead to identifying the patient.

Question Title

* 1. Have you been diagnosed with Mycosis Fungoides (MF) Cutaneous T-Cell Lymphoma?

T